Table 1 Unit cost and health-utility values used for the economic analysis
Category | Tariff | Origin |
|---|---|---|
Costs | ||
Gemcitabine | €0.24/mg | National reimbursement price [21] |
Erlotinib 30-day supply (150 mg) | €2174.70 | National reimbursement price [21] |
Pemetrexed | €2.45/mg | National reimbursement price [21] |
GCS-F | €185.80/inj | National reimbursement price [21] |
Epoetin | €221.2/inj | National reimbursement price [21] |
DRG for transfusion | €697.10 | DRG 11th edition [22] |
DRG for outpatient drug administration | €400.70 | DRG 11th edition [22] |
Palliative care (per month) | €2324 [€1627–€3021] | Chouaïd [23] |
Health-utility values | ||
Maintenance therapy | ||
Observation | 0.693 [0.46–0.88] | Nafees et al. [24] |
IV chemotherapy (gemcitabine) | 0.653 [0.26–0.78] | Nafees et al. [24] |
Oral chemotherapy (erlotinib) | 0.673 [0.27–0.80] | Nafees et al. [24] |
Second-line therapy | ||
IV chemotherapy (pemetrexed) | 0.653 [0.26–0.78] | Nafees et al. [24] |
Palliative care | 0.473 [0.19–0.56] | Nafees et al. [24] |
Death | 0 |